Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin, DPP-IVi, Dual/triple agonist, SGLT2i

Merck Q3 ’18 Earnings Update; No BS-Glargine Discussion

Here is a brief preview of this blast: Merck hosted its Q3 ’18 earnings call and only briefly discussed its diabetes business. Of note, this is the first time in recent memory that Merck has provided an accompanying slide presentation with its earnings release. Consistent with previous quarters, nearly all of the event was dedicated to Keytruda, and there was no discussion of Merck's discontinuation of bs-glargine. Below are highlights from the call.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.